About Halozyme

Helen Torley , , M.B. Ch. B., M.R.C.P. , , President, Chief Executive Officer and member of the Board of Directors

Dr. Torley brings extensive commercial and business experience as well as an extensive knowledge of the biotechnology industry. Dr. Torley joined Halozyme in January 2014 as President and Chief Executive Officer. Throughout her career, Dr. Torley has led several successful product launches, including Kyprolis®, Prolia®, Sensipar®, and Miacalcin®. Prior to joining Halozyme, Dr. Torley served as Executive Vice President and Chief Commercial Officer for Onyx Pharmaceuticals (Onyx) from August 2011 to December 2013 overseeing the collaboration with Bayer on Nexavar® and Stivarga® and the U.S. launch of Kyprolis. She was responsible for the development of Onyx's commercial capabilities in ex-US markets and in particular, in Europe. Prior to Onyx, Dr. Torley spent 10 years in management positions at Amgen Inc., most recently serving as Vice President and General Manager of the US Nephrology Business Unit from 2003 to 2009 and the U.S. Bone Health Business Unit from 2009 to 2011. From 1997 to 2002, she held various senior management positions at Bristol-Myers Squibb, including Regional Vice President of Cardiovascular and Metabolic Sales and Head of Cardiovascular Global Marketing. She began her career at Sandoz/Novartis, where she ultimately served as Vice President of Medical Affairs, developing and conducting post-marketing clinical studies across all therapeutic areas, including oncology. Before joining the industry, Dr. Torley was in medical practice as a senior registrar in rheumatology at the Royal Infirmary in Glasgow, Scotland. Dr. Torley received her Bachelor of Medicine and Bachelor of Surgery degrees (M.B. Ch.B.) from the University of Glasgow and is a Member of the Royal College of Physicians (M.R.C.P).

Athena Countouriotis , , M.D. , , Senior Vice President & Chief Medical Officer

Dr. Countouriotis joined Halozyme in January 2015 as Senior Vice President, Chief Medical Officer. Dr. Countouriotis has participated in or led the clinical development and approvals of three oncology assets (Bosulif®, Sutent®, and Sprycel®). Most recently, Dr. Countouriotis served as Chief Medical Officer at Ambit Biosciences (acquired by Daiichi Sankyo in November 2014) where she was responsible for clinical development, and regulatory affairs. In this capacity, Dr. Countouriotis provided leadership to the development and clinical operations strategies for quizartinib, currently in Phase 3 development for Acute Myeloid Leukemia, and served as a key contributor to the successful initial public offering in May 2013. Prior to her role at Ambit Biosciences, Dr. Countouriotis served as global clinical leader for the Oncology Business Unit of Pfizer Inc. In this role, she led late-stage clinical development and the approvals for Bosulif in Chronic Myelogenous Leukemia. In addition, Athena was a clinical leader for Sutent, participating in a successful U.S. Food and Drug Administration advisory committee meeting leading to the approval of Sutent in pancreatic neuroendocrine tumors. Dr. Countouriotis received her M.D. from Tufts University School of Medicine and her bachelor’s degree from the University of California, Los Angeles. She received her initial training in pediatrics at the University of California, Los Angeles, and additional training in the pediatric hematology/oncology program at the Fred Hutchinson Cancer Research Center.

William J. Fallon , , , Vice President, Manufacturing & Operations

Mr. William Fallon joined Halozyme in 2006 as Vice President, Manufacturing & Operations. His responsibilities include oversight of all aspects of internal and external manufacturing and facilities operations, as well as bioprocess development. Prior to Halozyme, he served as President and Chief Executive Officer of Cytovance Biologics, a contract manufacturing organization that provides manufacturing and development services to the biotechnology industry. From 2001 to 2003, he was Vice President of Technical Operations at Genzyme Corporation, having held the same position at Novazyme Pharmaceuticals, Inc. prior to its acquisition by Genzyme in 2001. Mr. Fallon joined Novazyme from Transkaryotic Therapies, where he was Vice President of Manufacturing from 1998 to 2001. From 1993 to 1998, he was employed in several management positions for the Ares-Serono Group, including Vice President, U.S. Manufacturing Operations. In this role, he served as general manager, overseeing the production and distribution of all of Serono's approved biotechnology products in the U.S. From 1990 to 1992, he was Director of Manufacturing for Centocor, Inc. His prior experience also includes various management and operational roles at Invitron Corporation and Travenol-Genentech Diagnostics. Mr. Fallon earned a B.S. in marine science and a B.A. in biology from Long Island University, and an M.S. in biology from Northeastern University.

Sunil Joshi , , , Vice President, Oncology, Global Product Team Lead

Mr. Joshi joined Halozyme in 2014 as Vice President, Oncology, Global Product Team Lead. Prior to joining Halozyme, Mr. Joshi was the head of New Product Strategy & Commercial Assessments at Onyx Pharmaceuticals, a subsidiary of Amgen. Before arriving at Onyx, Mr. Joshi spent 21 years at Bristol-Myers Squibb in various positions of increasing responsibility including US Sales and Marketing, Global Marketing & International Operations. From 2008 to 2012, Mr. Joshi served as Head of Oncology Business Unit for Intercontinental Markets leading the launch & commercial development of the oncology and hematology franchise including Ixempra®, Yervoy®, Erbitux® and Sprycel® across Intercontinental markets. Mr. Joshi has drug development experience in multiple therapeutic areas including oncology, metabolic diseases & anti-infectives, having worked on compounds from early to late stages of development. Mr. Joshi has a Masters in Science from Bombay University, India, and MBA from University of Akron, United States.

Michael J. LaBarre , , Ph.D. , , Vice President, Product Development

Dr. Michael LaBarre joined Halozyme in 2008 and oversees all of Halozyme’s product development efforts, bringing strong expertise in chemistry, manufacturing and controls (CMC) based on his extensive experience in the biotechnology industry for both biologics and small molecules. In his previous role as Vice President of Product Development at Paramount BioSciences, LLC, Dr. LaBarre led the CMC efforts for all of the product development programs within Paramount’s portfolio. Prior to joining Paramount, Dr. LaBarre served in various research and development positions from 1995 to 2006 at Biogen Idec (previously IDEC), where he had responsibility for analytical and formulation development, protein purification, and biochemical characterization supporting numerous IND and BLA submissions, including those for Rituxan® and Zevalin®. His last position with Biogen Idec was Director of Analytical and Protein Biochemistry. Prior to IDEC, Dr. LaBarre spent two years at Vical, Inc. in the analytical methods development group. He began his career at Hybritech, where he held positions in regulatory affairs and manufacturing technical support, focusing on radiolabeled antibody technologies and analytical chemistry. Dr. LaBarre received his B.S. in chemistry from Southampton College and his Ph.D. in bioinorganic chemistry from the University of Arizona.

Anita W. Matheson , , , Vice President, Human Resources

Ms. Matheson brings strong expertise in Human Resources based on her extensive experience in the biotechnology industry. Ms. Matheson joined Halozyme in February 2007 and oversees all Human Resources efforts for the company. Prior to joining Halozyme, Ms. Matheson served as the Senior Director, Human Resources at Exelixis and held the same position at X-Ceptor Therapeutics from 1999 to 2004, prior to its acquisition by Exelixis. Prior to joining X-Ceptor, Ms. Matheson served as the Director of Human Resources at Axys Pharmaceuticals. From 1993 to 1998, Ms. Matheson held the positions of Director of Human Resources, Associate Director of Human Resources, Manager of Human Resources and Administrative Director with Sequana Therapeutics (predecessor company to Axys Pharmaceuticals). Prior to that, from 1986 to 1993, she held various positions within finance and accounting at Software Products International. Her prior experience also includes positions within the sales and marketing division of A/S Denofa Lilleborg Fabriker in Oslo, Norway. Ms. Matheson has a baccalaureate degree in business and foreign languages from Norway, and a certificate in Human Resource Management from University of California, San Diego.

David A. Ramsay , , , Vice President, Chief Financial Officer

Mr. Ramsay joined Halozyme in 2003 as Chief Financial Officer and served in that capacity until 2009 when he was appointed Vice President, Corporate Development. After spending four years in various commercial and operational roles, Mr. Ramsay was appointed Chief Financial Officer. Prior to Halozyme, he served in various financial roles including Vice President, Chief Financial Officer of Lathian Systems. Prior to Lathian, Mr. Ramsay was Vice President, Treasurer of ICN Pharmaceuticals, now called Valeant Pharmaceuticals International, a multinational, specialty pharmaceutical company. Mr. Ramsay joined Valeant from ARCO, where he spent four years in various financial roles, most recently serving as Manager, Financial Planning & Analysis for the company’s Retail Marketing division. Prior to ARCO, he served as Vice President, Controller for Security Pacific Asian Bank, a subsidiary of Security Pacific Corporation. He began his career as an Auditor at Deloitte & Touche, where he obtained his CPA license. Mr. Ramsay received his B.S in Business Administration from the University of California, Berkeley, and his MBA in Finance and Strategic Management from The Wharton School at the University of Pennsylvania.

H. Michael Shepard, Ph.D. , , , Vice President, Chief Scientific Officer

Dr. H. Michael Shepard joined the company in 2009 as Vice President, Discovery Research with extensive experience in the biotechnology industry. He was promoted to Chief Scientific Officer in December 2010. Dr. Shepard has been a founder or co-founder of several biotechnology companies and his work has included protein therapeutics (Receptor BioLogix, Inc., 2003-2008), small molecules (NewBiotics, Inc., 1997-2002), gene therapy (Canji, Inc./Schering-Plough Corporation, 1992-1997), and monoclonal antibody therapeutics (Genentech, Inc. 1980-1992). While at Genentech, Dr. Shepard participated in many of the early programs that transformed Genentech into a commercial success. Among his most important accomplishments was the description of a key mechanism by which tumor cells can escape the host immune system. This work led to the discovery of the breast cancer drug Herceptin® (trastuzumab). In 2007, Dr. Shepard shared the Warren Alpert Prize from Harvard Medical School in recognition of this achievement. Dr. Shepard received his bachelor’s degree in zoology from the University of California, Davis and his Ph.D. in Molecular, Cellular and Developmental Biology from Indiana University. Dr. Shepard was also a postdoctoral fellow at Indiana University, supported by the Damon Runyon Cancer Research Foundation.

Kenneth A. Schultz , , M.D. , , Vice President of Innovation, Strategy and Business Development

Kenneth A. Schultz, M.D., joined Halozyme in January 2015 as Vice President of Innovation, Strategy and Business Development. From 2013-2014, Dr. Schultz held roles of increasing responsibility with Medtronic Diabetes, where he most recently served as Chief of Staff, Strategy, and Business Development and was responsible for identifying and evaluating novel therapies to purchase, entering the type 2 diabetes market, pursuing comprehensive partnerships, creating new service line strategies, and pursuing external investments. Prior to his role at Medtronic Diabetes, Dr. Schultz worked at McKinsey & Company from 2007-2012, where he provided consultative services to a range of global organizations across the medical device and pharmaceutical sectors. Dr. Schultz received his medical degree from Texas Tech University, an MBA from IMD in Switzerland and a bachelor’s degree from the Texas A&M University. Dr. Schultz began his career as a practicing physician. From 1999-2005, he worked in various positions including Vice-Chairman of Emergency Medicine with EMCare Physicians.